Sanderson Ralph D, Elkin Michael, Rapraeger Alan C, Ilan Neta, Vlodavsky Israel
Department of Pathology, Comprehensive Cancer Center, University of Alabama at Birmingham, AL, USA.
Sharett Oncology Institute, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
FEBS J. 2017 Jan;284(1):42-55. doi: 10.1111/febs.13932. Epub 2016 Nov 16.
Because of its impact on multiple biological pathways, heparanase has emerged as a major regulator of cancer, inflammation and other disease processes. Heparanase accomplishes this by degrading heparan sulfate which regulates the abundance and location of heparin-binding growth factors thereby influencing multiple signaling pathways that control gene expression, syndecan shedding and cell behavior. In addition, heparanase can act via nonenzymatic mechanisms that directly activate signaling at the cell surface. Clinical trials testing heparanase inhibitors as anticancer therapeutics are showing early signs of efficacy in patients further emphasizing the biological importance of this enzyme. This review focuses on recent developments in the field of heparanase regulation of cancer and inflammation, including the impact of heparanase on exosomes and autophagy, and novel mechanisms whereby heparanase regulates tumor metastasis, angiogenesis and chemoresistance. In addition, the ongoing development of heparanase inhibitors and their potential for treating cancer and inflammation are discussed.
由于其对多种生物学途径的影响,乙酰肝素酶已成为癌症、炎症及其他疾病进程的主要调节因子。乙酰肝素酶通过降解硫酸乙酰肝素实现这一作用,硫酸乙酰肝素可调节肝素结合生长因子的丰度和位置,从而影响控制基因表达、多配体蛋白聚糖脱落及细胞行为的多种信号通路。此外,乙酰肝素酶可通过直接激活细胞表面信号传导的非酶机制发挥作用。将乙酰肝素酶抑制剂作为抗癌疗法进行的临床试验已在患者中显示出早期疗效迹象,进一步凸显了这种酶的生物学重要性。本综述重点关注乙酰肝素酶在癌症和炎症调节领域的最新进展,包括乙酰肝素酶对外泌体和自噬的影响,以及乙酰肝素酶调节肿瘤转移、血管生成和化疗耐药性的新机制。此外,还讨论了乙酰肝素酶抑制剂的持续研发及其治疗癌症和炎症的潜力。